MBX Biosciences Inc. Comm... (MBX)
6.36
-0.61 (-8.75%)
At close: Apr 03, 2025, 3:59 PM
6.42
0.87%
Pre-market: Apr 04, 2025, 04:05 AM EDT
-8.75% (1D)
| Bid | 6.32 |
| Market Cap | 212.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -5.82 |
| PE Ratio (ttm) | -1.09 |
| Forward PE | -4.75 |
| Analyst | Buy |
| Ask | 6.46 |
| Volume | 193,380 |
| Avg. Volume (20D) | 269,995 |
| Open | 6.84 |
| Previous Close | 6.97 |
| Day's Range | 6.35 - 7.15 |
| 52-Week Range | 6.35 - 27.50 |
| Beta | -0.64 |
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developi...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 14, 2000
Employees 43
Stock Exchange NASDAQ
Ticker Symbol MBX
Website https://mbxbio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for MBX stock is "Buy." The 12-month stock price forecast is $37.5, which is an increase of 489.62% from the latest price.
Stock Forecasts4 months ago
+4.05%
MBX Biosciences shares are trading higher. The sto...
Unlock content with
Pro Subscription
